Dovato vs Paxlovid
A side-by-side look at two antiviral medications advertised on TV. Informational only — not medical advice.
| US Dovato | US Paxlovid | |
|---|---|---|
| Generic name | dolutegravir/lamivudine | nirmatrelvir/ritonavir |
| Drug class | Two-Drug HIV Regimen (INSTI/NRTI) | Antiviral Protease Inhibitor Combination |
| Treats | HIV-1 infection | COVID-19 (mild to moderate) |
| Category | Antiviral | Antiviral |
| Manufacturer | ViiV Healthcare | Pfizer |
| Year approved | 2019 | 2023 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $95M | $60M |
| Common side effects | Headache, Nausea, Diarrhea, Trouble sleeping | Altered taste, Diarrhea, High blood pressure, Muscle aches |
Frequently asked questions
Is Dovato or Paxlovid better?
Neither is universally "better." Dovato (dolutegravir/lamivudine) and Paxlovid (nirmatrelvir/ritonavir) are both used for antiviral, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dovato and Paxlovid?
Dovato is a Two-Drug HIV Regimen (INSTI/NRTI) made by ViiV Healthcare, while Paxlovid is a Antiviral Protease Inhibitor Combination made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dovato has the larger estimated TV advertising budget of the two.